Flagship’s Repertoire combines Cogen, Torque to pick antigens for immunotherapies

By combining TCR-antigen matching company Cogen with T cell therapy play Torque, Flagship Pioneering’s Repertoire Immune Medicines Inc. aims to boost the latter’s ongoing oncology programs while demonstrating clinical proof of concept for the former’s platform.

Flagship CEO and Repertoire co-founder Noubar Afeyan told BioCentury

Read the full 446 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE